上海宣泰医药科技股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、本次权益变动属于上海宣泰医药科技股份有限公司（以下简称"公司"） 持股 5%以上非第一大股东南京市栖和创业投资合伙企业（有限合伙）（以下简称 "栖和创业"）减持公司股份，不触及要约收购。 2、股东持股基本情况 本次权益变动后，栖和创业持有公司股份由 36,798,000 股减少至 36,222,814 股，占公司总股本的比例由 8.1171%减少至 7.9902%。 证券代码：688247 证券简称：宣泰医药 公告编号：2025-004 基于自身经营需要，公司股东栖和创业计划自 2024 年 12 月 19 日至 2025 年 3 月 18 日，通过集中竞价交易减持不超过 4,500,000 股，通过大宗交易方式减持不超 过 6,500,000 股。 注：1、减持股份来源：公司首次公开发行前股份； 2、本次权益变动所涉及公司股份均享有表决权，不存在表决权委托或受限 等任何权 ...

Revenue Forecast - The company expects 2024 annual revenue to be between 451.17 million and 541.40 million CNY, representing a year-over-year increase of 50% to 81%[3]. - In 2023, the company achieved a revenue of 299.87 million CNY and a net profit of 61.07 million CNY[5]. - The significant growth in revenue is attributed to the company's focus on domestic and international sales and increased income from major product sales and equity sharing[6]. Profit Forecast - The projected net profit attributable to the parent company for 2024 is expected to be between 115.41 million and 138.49 million CNY, an increase of 89% to 127% compared to the previous year[3]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is estimated to be between 103.20 million and 123.84 million CNY, reflecting a year-over-year increase of 117% to 161%[3]. CMO Revenue - The company has seen a notable increase in CMO revenue due to the commercialization of products from CRO/CMO clients[6]. Financial Data and Audit - The financial data in the performance forecast has not been audited by a registered accountant[4]. - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[8]. - As of the announcement date, the company has not identified any major uncertainties affecting the accuracy of the performance forecast[7]. Announcement Details - The announcement was made by the board of directors on January 23, 2025[10].

近日，上海宣泰医药科技股份有限公司（以下简称"公司"）参与了第十批国 家组织药品集中带量采购的投标。根据国家组织药品联合采购办公室于 2024 年 12 月 12 日发布的《全国药品集中采购拟中选结果公示》文件显示，公司产品碳 酸司维拉姆片、马昔腾坦片（公司与普济生物科技（台州）有限公司合作开发产 品）中选本次集中带量采购，泊沙康唑肠溶片、枸橼酸托法替布缓释片未中选本 次集中带量采购。本次集中带量采购中选结果拟于 2025 年 4 月实施，具体执行 日期以各地发布通知为准。现将有关情况公告如下： 一、中选产品基本情况 | 中选产品 | 适应症 | 规格包装 | | 中选价格 | | --- | --- | --- | --- | --- | | 碳酸司维拉姆片 | 用于控制正在接受透析治疗的慢 性肾脏病成人患者的高磷血症 | 0.8g*30 | 片/瓶 | 22.47 元/瓶 | | 马昔腾坦片 | 用于治疗肺动脉高压 | 10mg*15 板/盒 | 片/板*2 | 79.71 元/盒 | 二、本次带量采购对公司的影响 对于中选产品，碳酸司维拉姆片 2023 年中国市场销售收入为 0 元；2024 年 1-9 ...

上海宣泰医药科技股份有限公司 证券代码：688247 证券简称：宣泰医药 编号：2024-004 投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------------------|------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 □分析师会议 | | | 动类别 | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | □其他 （请文字说明其他活动内容） | | 参与单位名称 及人员 | 参加业绩说明会的投资者 | | | 时间 | 2024 年 12 月 6 日下午 | 2 点-3 点 | | 地点 | 上海证券交易所上证路演中心 （网址： | http://roadshow.sseinfo.com/ ） | | 上市公司接待 | | 董事长叶峻，总经理郭明洁，财务总监卫培华，董事会秘书 | | 人员姓名 | 李方立，独立董事张俊 | | | | ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-050 | 回购方案首次披露日 | 2024/2/21，由公司控股股东上海联和投资有限公 司提议 | | | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | | 预计回购金额 | 3,500 万元 | 万元~7,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 4,336,109 | 股 | | 累计已回购股数占总股本比 | 0.96% | | | 例 | | | | 累计已回购金额 | 3,612.60 | 万元 | | 实际回购价格区间 | 7.40 元/股 | 元/股~8.98 | 一、 回购股份的基本情况 公司于 2024 年 2 月 19 日召开第二届董事会第八次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证 券交易所股票交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 （A 股）股票，回 ...

证券时报e公司讯，宣泰医药(688247)11月27日晚间公告，持有公司8.12%股份的股东南京市栖和创业投 资合伙企业(有限合伙)计划通过集中竞价或大宗交易方式，减持公司股份不超过1100万股，占公司总股 本的比例不超过2.43%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-049 上海宣泰医药科技股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，上海宣泰医药科技股份有限公司（以下简称"宣泰医药" 或"公司"）股东南京市栖和创业投资合伙企业（有限合伙）（以下简称"栖和创 业"）持有公司股份 36,798,000 股，占公司总股本的 8.1171%。上述股份来源为 公司首次公开发行前取得的股份，已于 2023 年 8 月 25 日解除限售并上市流通。 减持计划的主要内容 公司于 2024 年 11 月 27 日收到栖和创业出具的《关于上海宣泰医药科技股 份有限公司股份减持计划的告知函》，因股东自身经营需要，栖和创业计划根据 市场情况拟通过集中竞价或大宗交易的方式减持其所持有的公司股份数量合计 不超过 11,000,000 股，拟减持股份数量占公司总股本的比例不超过 2.4264%。 其中以集中竞价方式减持的，减持期间为 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-048 上海宣泰医药科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一） 会议召开时间：2024 年 12 月 6 日(星期五) 下午 14:00-15:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：网络互动 会议召开时间：2024 年 12 月 6 日(星期五) 下午 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 29 日(星期五) 至 12 月 5 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过上海宣泰医药科技股份 有限公司（以下简称"公司"）邮箱 info@sinotph.com 进行提问。公司将在说明 会上对投资者普 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-047 上海宣泰医药科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/21，由公司控股股东上海联和投资有限公 司提议 | | | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | | 预计回购金额 | 3,500 万元 | 万元~7,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 4,336,109 | 股 | | 累计已回购股数占总股本比 | 0.96% | | | 例 | | | | 累计已回购金额 | 3,612.60 | 万元 | | 实际回购价格区间 | 7.40 元/股 | 元/股~8.98 | 一、 回购股份的基本情况 公司于 2024 年 2 月 19 日召开第 ...

Financial Performance - Revenue for Q3 2024 reached ¥144,613,579.11, an increase of 40.95% year-over-year, and cumulative revenue for the year-to-date was ¥362,608,213.87, up 69.95% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥38,419,639.84, reflecting an 80.46% increase year-over-year, with a year-to-date net profit of ¥92,572,974.72, up 110.00%[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥36,245,851.54, a 93.81% increase year-over-year, while the year-to-date figure was ¥85,039,247.10, up 130.39%[2]. - Basic earnings per share for Q3 2024 was ¥0.09, an increase of 80.00% year-over-year, with a year-to-date figure of ¥0.21, up 110.00%[3]. - The company reported total operating revenue of CNY 362,608,213.87 for the first nine months of 2024, a significant increase of 69.8% compared to CNY 213,364,344.65 in the same period of 2023[15]. - Total comprehensive income for Q3 2024 was CNY 92,583,577.38, significantly higher than CNY 44,136,578.61 in Q3 2023, marking an increase of 109.1%[18]. - Operating profit for Q3 2024 reached CNY 102,768,011.67, compared to CNY 47,892,033.36 in Q3 2023, reflecting an increase of 114.5%[17]. Research and Development - Total R&D investment for Q3 2024 was ¥22,407,526.38, a 41.76% increase year-over-year, with cumulative R&D investment for the year-to-date at ¥56,471,663.02, up 30.08%[3]. - The proportion of R&D investment to revenue for Q3 2024 was 15.49%, an increase of 0.09 percentage points year-over-year, while the year-to-date ratio was 15.57%, a decrease of 4.77 percentage points[3]. - Research and development expenses for Q3 2024 amounted to CNY 56,471,663.02, up from CNY 43,413,700.00 in Q3 2023, indicating a year-over-year increase of 30.1%[17]. Cash Flow and Assets - The company reported a notable increase in cash flow from operating activities, with a year-to-date net cash flow of ¥87,829,748.53, reflecting a 134.87% increase year-over-year[2]. - The company's cash and cash equivalents decreased to CNY 297,635,969.73 as of September 30, 2024, from CNY 641,783,808.70 at the end of 2023, representing a decline of 53.6%[14]. - The net cash flow from investing activities for the first nine months of 2024 was CNY -377,570,473.13, an improvement compared to CNY -632,217,115.16 in the same period of 2023[21]. - Non-current assets totaled CNY 428,349,025.37 as of September 30, 2024, an increase from CNY 409,611,514.21 at the end of 2023, reflecting a growth of 4.7%[14]. - The total assets of the company reached CNY 1,429,473,540.68, up from CNY 1,361,620,252.55, representing an increase of 5%[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,986[8]. - Shanghai Lianhe Investment Co., Ltd. holds 233,000,000 shares, accounting for 51.40% of the total shares[8]. - Finer Pharma Inc. is the second-largest shareholder with 70,437,870 shares, representing 15.54%[9]. - Nanjing Qihe Venture Investment Partnership holds 36,798,000 shares, which is 8.12% of the total[9]. - The company has repurchased 4,336,109 shares, which is 0.96% of the total shares[10]. - The top ten shareholders include various entities, with the largest being state-owned and foreign entities[11]. - The report indicates that there are no significant changes in the shareholding structure compared to the previous period[12]. - The total number of shares held by the top ten unrestricted shareholders is significant, indicating a concentrated ownership structure[11]. Financial Position - Total operating costs for the first nine months of 2024 were CNY 266,457,899.41, up from CNY 174,363,154.22 in the previous year, reflecting a year-over-year increase of 52.8%[15]. - The company's total liabilities amounted to CNY 192,422,177.59, compared to CNY 151,361,317.13 in the previous year, showing an increase of 27.2%[15]. - The company’s retained earnings increased to CNY 282,522,243.15 from CNY 219,593,425.24, reflecting a growth of 28.6% year-over-year[15]. Market Developments - Significant revenue growth was attributed to the successful bidding of ursodeoxycholic acid capsules in the national drug procurement program and the inclusion of posaconazole enteric-coated tablets in the national medical insurance catalog[7]. - The company received formal approval for the Dapagliflozin Metformin Extended-Release Tablets, becoming the first domestic company to obtain approval for this generic drug[13].